A Program for Individual and Population Optimal Design for Univariate and Multivariate Response Pharmacokinetic-pharmacodynamic Models

Overview

Journal Comput Methods Programs Biomed

Specialty Medical Informatics

Date 2007 Feb 13

PMID 17292995

Citations 22

Authors

Ivelina Gueorguieva

Kayode Ogungbenro

Gordon Graham

Sophie Glatt

Leon Aarons

Affiliations

Soon will be listed here.

Abstract

The design of pharmacokinetic and pharmacodynamic experiments concerns a number of issues, among which are the number of observations and the times when they are taken. Often a model is used to describe these data and the pharmacokinetic-pharmacodynamic behavior of a drug. Knowledge of the data analysis model at the design stage is beneficial for collecting patient data for parameter estimation. A number of criteria for model-oriented experiments, which maximize the information content of the data, are available. In this paper we present a program, Popdes, to investigate the D-optimal design of individual and population multivariate response models, such as pharmacokinetic-pharmacodynamic, physiologically based pharmacokinetic, and parent drug and metabolites models. A pre-clinical and clinical pharmacokinetic-pharmacodynamic model describing the concentration-time profile and effect of an oncology compound in development is used for illustration.

Citing Articles

Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis.

Ling S, Ogungbenro K, Darwich A, Ariff A, Nair N, Bluett J Pharmaceutics. 2024; 16(6).

PMID: 38931826 PMC: 11206727. DOI: 10.3390/pharmaceutics16060702.

Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?.

Kontou A, Sarafidis K, Begou O, Gika H, Tsiligiannis A, Ogungbenro K Antimicrob Agents Chemother. 2020; 64(4).

PMID: 31932366 PMC: 7179285. DOI: 10.1128/AAC.01971-19.

Optimal Design for Informative Protocols in Xenograft Tumor Growth Inhibition Experiments in Mice.

Lestini G, Mentre F, Magni P AAPS J. 2016; 18(5):1233-1243.

PMID: 27306546 PMC: 5660732. DOI: 10.1208/s12248-016-9924-z.

Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist.

Ogungbenro K, Hulme S, Rothwell N, Hopkins S, Tyrrell P, Galea J J Pharmacokinet Pharmacodyn. 2015; 43(1):1-12.

PMID: 26476629 DOI: 10.1007/s10928-015-9450-0.

Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.

Lestini G, Dumont C, Mentre F Pharm Res. 2015; 32(10):3159-69.

PMID: 26123680 PMC: 5385211. DOI: 10.1007/s11095-015-1693-3.